Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

View recent presentations and learn more about upcoming events.

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search ...

The primary objective of this Collaborative Working Project (“CWP”) is to is to improve the quality and equity of care for patients and support the early identification, review, and medical ...

Utforsk mulighetene hos Novartis og Sandoz her. Se mer informasjon om stillinger hos Novartis Gene Therapies på GTx Career Search.

Production and phased deliveries of patient doses resumed in early June Screening and enrollment have restarted for 177Lu-PSMA-617 and Lutathera® clinical trials Expanding radioligand therapy ...

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer ...

Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3 Cardiovascular disease causes 3.9 million ...

Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey This action has been taken out of an abundance of ...